- Home
- XERS vs VRDN Comparison
XERS vs VRDN Comparison
Compare XERS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- VRDN
- Stock Information
- Founded
- XERS 2005
- VRDN 2006
- Country
- XERS United States
- VRDN United States
- Employees
- XERS N/A
- VRDN N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- XERS Health Care
- VRDN Health Care
- Exchange
- XERS Nasdaq
- VRDN Nasdaq
- Market Cap
- XERS 1.3B
- VRDN 1.5B
- IPO Year
- XERS 2018
- VRDN N/A
- Fundamental
- Price
- XERS $7.36
- VRDN $18.01
- Analyst Decision
- XERS Strong Buy
- VRDN Strong Buy
- Analyst Count
- XERS 7
- VRDN 11
- Target Price
- XERS $8.00
- VRDN $38.80
- AVG Volume (30 Days)
- XERS 1.9M
- VRDN 875.0K
- Earning Date
- XERS 11-07-2025
- VRDN 11-11-2025
- Dividend Yield
- XERS N/A
- VRDN N/A
- EPS Growth
- XERS N/A
- VRDN N/A
- EPS
- XERS N/A
- VRDN N/A
- Revenue
- XERS $246,025,000.00
- VRDN $305,000.00
- Revenue This Year
- XERS $43.89
- VRDN N/A
- Revenue Next Year
- XERS $20.40
- VRDN $35,092.81
- P/E Ratio
- XERS N/A
- VRDN N/A
- Revenue Growth
- XERS 35.62
- VRDN 5.90
- 52 Week Low
- XERS $2.69
- VRDN $9.90
- 52 Week High
- XERS $8.03
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- XERS 51.35
- VRDN 45.76
- Support Level
- XERS $7.56
- VRDN $18.12
- Resistance Level
- XERS $7.89
- VRDN $20.51
- Average True Range (ATR)
- XERS 0.24
- VRDN 0.93
- MACD
- XERS -0.14
- VRDN -0.12
- Stochastic Oscillator
- XERS 2.90
- VRDN 3.85
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).